Literature DB >> 21620442

Safety and efficacy of warfarin in paediatric patients with prosthetic cardiac valves: a retrospective audit.

Centison S Wong1, Kate Batchelor, Jim Bua, Fiona Newall.   

Abstract

INTRODUCTION: Guidelines for warfarin management in children are essentially extrapolated from adult evidence. This study aimed to address that lack of paediatric-specific data regarding warfarin safety and efficacy for this population.
MATERIALS AND METHODS: A retrospective clinical audit was conducted within a cardiac referral centre incorporating a paediatric anticoagulation service. Children (0-16 years) with a prosthetic cardiac valve were included. Warfarin related outcomes were collected between January 1st 2004 and December 31st 2009. Analysis included the percentage of INR tests within, above, or below the target therapeutic range (TTR). Adverse event data was collected regarding major bleeding and thrombotic events.
RESULTS: 75 patient years of warfarin therapy were recorded. 44.0% of INR tests were within the TTR. INR tests not within the TTR were twice as likely to be sub-therapeutic. Children with aortic prosthetic valves achieved their TTR less frequently than children with prosthetic mitral or tricuspid valves. There were no thrombotic events and 3 major bleeding events.
CONCLUSIONS: Although less than 50% of INR results were within the TTR, oral anticoagulant management resulted in acceptable safety and efficacy outcomes for this cohort. Further studies are needed to confirm optimal paediatric-specific warfarin management strategies for children with prosthetic heart valves. Crown
Copyright © 2011. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21620442     DOI: 10.1016/j.thromres.2011.04.020

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  6 in total

1.  Impact of dengue-induced thrombocytopenia on mandatory anticoagulation for patients with prosthetic heart valves on warfarin.

Authors:  Tammy S H Lim; Robert T Grignani; Paul A Tambyah; Swee-Chye Quek
Journal:  Singapore Med J       Date:  2015-04       Impact factor: 1.858

2.  CSI consensus statement on prosthetic valve follow up.

Authors:  Rajiv Bajaj; G Karthikeyan; Nakul Sinha; Yash Lokhandwala; Dayasagar Rao; S K Kaushik; S L Jain; Shashi Narayanan; Ashok Seth; I Satyamurthi; J P S Sawhney; R K Saran; Satyavan Sharma; K K Haridas; R K Gohkroo; A K Omar; S K Dwivedi; Sunil Modi; K K Kapur; Bharat Dalvi; Anil Bharani; G S Wander; K Venugopal; T S Mahant
Journal:  Indian Heart J       Date:  2012-11-12

Review 3.  A Narrative Review of Postoperative Anticoagulation Therapy for Congenital Cardiac Disease.

Authors:  Alexander A Boucher; Julia A Heneghan; Subin Jang; Kaitlyn A Spillane; Aaron M Abarbanell; Marie E Steiner; Andrew D Meyer
Journal:  Front Surg       Date:  2022-06-14

4.  Influence of two common polymorphisms in the EPHX1 gene on warfarin maintenance dosage: a meta-analysis.

Authors:  Hong-Qiang Liu; Chang-Po Zhang; Chang-Zhen Zhang; Xiang-Chen Liu; Zun-Jing Liu
Journal:  Biomed Res Int       Date:  2015-01-06       Impact factor: 3.411

5.  Personalised Warfarin Dosing in Children Post-cardiac Surgery.

Authors:  Basma Zuheir Al-Metwali; Peter Rivers; Larry Goodyer; Linda O'Hare; Sanfui Young; Hussain Mulla
Journal:  Pediatr Cardiol       Date:  2019-10-05       Impact factor: 1.655

6.  Gene-based anticoagulation regimens for an infant after mitral-valve replacement: A case report.

Authors:  Hua Cao; Xiaotong Xia; Jinglan Fu; Tingting Wu; Wenjun Chen; Ying Dai; Xuan Xia; Jinhua Zhang
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.